Soterix Medical Inc. announces today a multi-center trial for Depression. The largest multi-center tDCS trial to date is investigator initiated by Dr. Colleen Loo at the Black Dog Institute at The University of South Wales with additional sites including Duke University, Emory University, Sheppard Pratt Health System, University of Medicine and Dentistry New Jersey, and the University of Texas. This study build on prior work suggesting tDCS has antidepressant efficacy in a 3 week double-blind,randomized,sham-controlled trial.

Dr. Abhishek Datta, CTO of Soterix Medical summarizes “This study will be the largest and most rigorous clinical trial of tDCS to-date. For this trial, the Soterix Medical 1x1 CT will provide optimized control of stimulation dose with additional double-blind and study-control features unique to the CT. The study will include Soterix Medical Limited Total Energy (LTE) intelligent ramp technology and leverage the easy to use EASYStrap platform.”

From the Black Dog Institute: “New Trial of Non-Medication Treatment for Depression – Direct Current Stimulation. Researchers are investigating direct current stimulation (DCS) as a treatment for depression and potential alternative to medication and electroconvulsive therapy. The stimulation is painless with no known serious side effects (some people report a headache afterwards), and the person is fully awake and alert during the 30 minute treatment sessions.”

From ClinicalTrials.Gov “Transcranial direct current stimulation (tDCS) is a novel treatment approach for depression that has shown promising efficacy in four recent double-blind, randomized, sham-controlled trials (RCT) and a meta-analysis. This study is a RCT of tDCS in depressed patients, testing its efficacy in both unipolar and bipolar depression. Mood, cognitive test performance and biomarkers will be measured during the trial.”

Media Contact
Narges Ghazi
Email: contact@soterixmedical.com